公开(公告)号：US20200038481A1

公开(公告)日：2020-02-06

申请号：US16348106

申请日：2017-11-10

Applicant: CSL LIMITED

Inventor： Samuel Wright ,  Charles Shear ,  Denise D'Andrea ,  Andreas Gille ,  Danielle Duffy

IPC: A61K38/17 ,  A61K9/00 ,  A61K47/26 ,  A61K47/28 ,  A61K31/685 ,  A61K45/06 ,  A61K31/397 ,  A61P9/10 ,  A61P3/06 ,  A61K31/216 ,  A61K31/192 ,  A61K31/366 ,  A61K31/727 ,  A61K31/40 ,  A61K31/505 ,  A61K31/47

Abstract: Reconstituted HDL formulations, methods of treatment comprising same and uses thereof are provided for treating patients after an acute myocardial infarction (MI) event. The reconstituted HDL formulations comprise an apo lipoprotein, a lipid, a detergent and a stabilizer such as sucrose. Treatment of MI patients with repeated infusions of rHDL enhance cholesterol efflux capacity and do not produce significant alterations in liver or kidney function. The MI patient may have normal kidney function or moderate renal impairment.

公开(公告)号：US20240207357A1

公开(公告)日：2024-06-27

申请号：US18230058

申请日：2023-08-03

Applicant: CSL Limited

Inventor： Samuel Wright ,  Charles Shear ,  Denise D'Andrea ,  Andreas Gille ,  Danielle Duffy

IPC: A61K38/17 ,  A61K9/00 ,  A61K31/192 ,  A61K31/216 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  A61K31/47 ,  A61K31/505 ,  A61K31/685 ,  A61K31/727 ,  A61K45/06 ,  A61K47/26 ,  A61K47/28 ,  A61P3/06 ,  A61P9/10

CPC classification number: A61K38/1709 ,  A61K9/0019 ,  A61K31/192 ,  A61K31/216 ,  A61K31/366 ,  A61K31/397 ,  A61K31/40 ,  A61K31/47 ,  A61K31/505 ,  A61K31/685 ,  A61K31/727 ,  A61K45/06 ,  A61K47/26 ,  A61K47/28 ,  A61P3/06 ,  A61P9/10

Abstract: Reconstituted HDL formulations, methods of treatment comprising same and uses thereof are provided for treating patients after an acute myocardial infarction (MI) event. The reconstituted HDL formulations comprise an apo lipoprotein, a lipid, a detergent and a stabilizer such as sucrose. Treatment of MI patients with repeated infusions of rHDL enhance cholesterol efflux capacity and do not produce significant alterations in liver or kidney function. The MI patient may have normal kidney function or moderate renal impairment.